A method for constructing an animal model simulating human ischemic heart failure
By using biodegradable PLGA microspheres to establish coronary microemboli in a mouse model and combining them with early screening criteria, the stability and efficiency issues of simulating progressive ventricular remodeling and heart failure in existing technologies have been resolved, achieving low-cost and efficient model construction.
CN122096041APending Publication Date: 2026-05-29SHIJIAZHUANG INFORMATION ENG VOCATIONAL COLLEGE
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHIJIAZHUANG INFORMATION ENG VOCATIONAL COLLEGE
- Filing Date
- 2026-03-09
- Publication Date
- 2026-05-29
Smart Images
Figure CN122096041A_ABST
Abstract
The application discloses an animal model construction method simulating human ischemic heart failure, and relates to the field of biomedical experimental animal models, and comprises the following steps: S1, model construction: embolism suspension liquid containing microspheres with a specific diameter is injected into the left ventricular cavity of a target animal through percutaneous puncture, so that the microspheres are embolized in myocardial microvessels through coronary artery circulation, thereby establishing a coronary artery microembolism model; S2, early screening: within 24 hours after model construction, cardiac ultrasound detection and serum biomarker detection are performed on the target animal; the animal model construction method simulating human ischemic heart failure simulates embolism of human myocardial arterioles and capillary arterioles by controlling the particle size (15-45 mu m) of the microspheres, induces diffuse myocardial ischemia closer to the clinic, thereby stably leading to progressive ventricular remodeling and chronic heart failure, rather than acute transmural infarction.
Need to check novelty before this filing date? Find Prior Art